Intrathecal Pseudodelivery of Drugs in the Therapy of Neurodegenerative Diseases: Rationale, Basis and Potential Applications
Menéndez-González Manuel,
Bogdan-Ionel Tamba,
Maxime Leclere,
Mostafa Mabrouk,
Thomas-Gabriel Schreiner,
Romeo Ciobanu,
Tomás-Zapico Cristina
Affiliations
Menéndez-González Manuel
Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Calle Julián Clavería s/n, 33006 Oviedo, Spain
Bogdan-Ionel Tamba
Advanced Research and Development Center for Experimental Medicine (CEMEX), “Grigore T. Popa” University of Medicine and Pharmacy, Universitatii Str., No. 16, 700155 Iasi, Romania
Maxime Leclere
Adaptative Supramolecular Nanosystems Group, Institut Europeen des Membranes, University of Montpellier, ENSCM-CNRS, Place E. Bataillon CC047, 34095 Montpellier, France
Mostafa Mabrouk
Refractories, Ceramics and Building Materials Department, National Research Centre, 33 El Bohouth St. (Former EL Tahrir St.), Dokki, Giza 12622, Egypt
Thomas-Gabriel Schreiner
Faculty of Medicine, University of Medicine and Pharmacy “Carol Davila”, 050474 Bucharest, Romania
Romeo Ciobanu
Department of Electrical Measurements and Materials, Faculty of Electrical Engineering and Information Technology, Gheorghe Asachi Technical University of Iasi, 700050 Iasi, Romania
Tomás-Zapico Cristina
Facultad de Medicina y Ciencias de la Salud, Universidad de Oviedo, Calle Julián Clavería s/n, 33006 Oviedo, Spain
Intrathecal pseudodelivery of drugs is a novel route to administer medications to treat neurodegenerative diseases based on the CSF-sink therapeutic strategy by means of implantable devices. While the development of this therapy is still in the preclinical stage, it offers promising advantages over traditional routes of drug delivery. In this paper, we describe the rationale of this system and provide a technical report on the mechanism of action, that relies on the use of nanoporous membranes enabling selective molecular permeability. On one side, the membranes do not permit the crossing of certain drugs; whereas, on the other side, they permit the crossing of target molecules present in the CSF. Target molecules, by binding drugs inside the system, are retained or cleaved and subsequently eliminated from the central nervous system. Finally, we provide a list of potential indications, the respective molecular targets, and the proposed therapeutic agents.
